TY - JOUR
T1 - Scientific research in malaria
T2 - Bibliometric assessment of the Latin-American contributions
AU - Muñoz-Urbano, Marcela
AU - López-Isaza, Andrés F.
AU - Hurtado-Hurtado, Natalia
AU - Gómez-Suta, Daniela
AU - Murillo-Abadia, Jonathan
AU - Delgado-Osorio, Nathalia
AU - Lagos-Grisales, Guillermo J.
AU - Villegas, Soraya
AU - Medina-Morales, Diego A.
AU - Rodríguez-Morales, Alfonso J.
N1 - Publisher Copyright:
© 2014 Bentham Science Publishers.
PY - 2015
Y1 - 2015
N2 - Background: Malaria is a parasitic disease of high global impact in public health, including Latin America. There should be more researched, particularly in this region. A bibliometric assessment of the Latin American contributions about malaria was done. Methods: Bibliometric study at SCI (1980-2013), MEDLINE/ GOPUBMED (1802-2013), Scopus (1959-2013), SCIELO (2004-2013), LILACS (1980-2013). The studies were characterized by study type, year of publication, city/country of origin, journals and more productive authors, citations and H index. Results: At SCI, 2,806 articles were retrieved (5.13% of the total). Brazil was the highest producer (31.41%), followed by Colombia (14.3%) and Mexico (9.5%). The region received 39,894 citations, 32.2% from Brazil (H index=51), 12.75% Mexico (H index=38), 11.2% Colombia (H index=33). At Scopus, there are 4,150 articles (4.9% of the total), 33.0% Brazil, 11.3% Colombia and 8.8% Mexico; 17% in Brazil were from Universidad de São Paulo; 23.6% of Colombia from Universidad de Antioquia; 15.4% of Mexico from Instituto Nacional de Salud Pública. At Medline there were 4,278 records (36.8% Brazil). At SciELO there are 792 records (45.3% Brazil). At LILACS there were 1744 records (34.3% Brazil). Conclusions: Brazil has the highest output of the region, as Venezuela the scientific production in Malaria was related with the burden of disease. This was not the case for Colombia. Scientific production at bibliographical databases, particularly regionals, is low, compared to the high incidence of this disease that requires more research and control.
AB - Background: Malaria is a parasitic disease of high global impact in public health, including Latin America. There should be more researched, particularly in this region. A bibliometric assessment of the Latin American contributions about malaria was done. Methods: Bibliometric study at SCI (1980-2013), MEDLINE/ GOPUBMED (1802-2013), Scopus (1959-2013), SCIELO (2004-2013), LILACS (1980-2013). The studies were characterized by study type, year of publication, city/country of origin, journals and more productive authors, citations and H index. Results: At SCI, 2,806 articles were retrieved (5.13% of the total). Brazil was the highest producer (31.41%), followed by Colombia (14.3%) and Mexico (9.5%). The region received 39,894 citations, 32.2% from Brazil (H index=51), 12.75% Mexico (H index=38), 11.2% Colombia (H index=33). At Scopus, there are 4,150 articles (4.9% of the total), 33.0% Brazil, 11.3% Colombia and 8.8% Mexico; 17% in Brazil were from Universidad de São Paulo; 23.6% of Colombia from Universidad de Antioquia; 15.4% of Mexico from Instituto Nacional de Salud Pública. At Medline there were 4,278 records (36.8% Brazil). At SciELO there are 792 records (45.3% Brazil). At LILACS there were 1744 records (34.3% Brazil). Conclusions: Brazil has the highest output of the region, as Venezuela the scientific production in Malaria was related with the burden of disease. This was not the case for Colombia. Scientific production at bibliographical databases, particularly regionals, is low, compared to the high incidence of this disease that requires more research and control.
KW - Bibliometrics
KW - Epidemiology
KW - Latin America
KW - Malaria
UR - http://www.scopus.com/inward/record.url?scp=84930511152&partnerID=8YFLogxK
U2 - 10.2174/1574891X10666150410165038
DO - 10.2174/1574891X10666150410165038
M3 - Artículo
C2 - 25858269
AN - SCOPUS:84930511152
SN - 1574-891X
VL - 9
SP - 209
EP - 215
JO - Recent Patents on Anti-Infective Drug Discovery
JF - Recent Patents on Anti-Infective Drug Discovery
IS - 3
ER -